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E D I T O R I A L
Th e digitization of the 
Pharmaceutical Historian archive
Th is number of Pharmaceutical Historian marks anoth-
er important milestone in the history of this journal. 
Th e fi rst number of volume 1 appeared in October 
1967, and it has appeared regularly ever since, and quar-
terly from volume 13 in 1983. A fi rst index of its con-
tents was published in 1996, covering the fi rst 29 years, 
up to volume 26. Th ereafter an index has been pub-
lished at 5 yearly intervals, which in recent years has 
been available on the BSHP website. But until now ac-
cess to the journal itself has depended on the availabil-
ity of a hard copy, which for many researchers has 
meant a trip to a distant library. 
Pharmaceutical Historian 1967 to 2016
We are therefore pleased to announce that the digiti-
zation of the complete Pharmaceutical Historian ar-
chive, from 1967 to the end of 2016, has now been 
completed. Th e entire archive is available online on an 
open access basis. Th e work has been very generously 
carried out at the Technische Universität Braunsch-
weig (Technical University of Braunschweig) in Ger-
many by Stefan Wulle and his team. Th e archive itself 
is being kindly hosted on the University of Braunsch-
weig Library server.
Th e archive can be accessed directly at the Technis-
che Universität Braunschweig at the following link: htt-
ps://publikationsserver.tu-braunschweig.de/receive/
dbbs_mods_65362 Alternatively it can be accessed in-
directly through the websites of either the Internation-
al Society for the History of Pharmacy (ISHP) and the 
British Society for the History of Pharmacy (BSHP). 
For ISHP go to https://histpharm.org/pharmaceutical-
historian/ and then click ‘archive’. For the BSHP web-
site go to the publications page at https://www.bshp.
org/publications/default.asp and then click ‘archive’.
Indexes to Pharmaceutical Historian 
Multi-year indexes for Pharmaceutical Historian are 
available on the BSHP website. Th e fi ve currently avail-
able cover the years 1967 to 1995, 1996 to 2000, 2001 
to 2005, 2006 to 2010 and 2011 to 2015 respectively. 
Th ey can be accessed at https://www.bshp.org/publica-
tions/Indexes.asp 
Indexes will continue to be produced on a fi ve-year-
ly basis. Th e next one will be for the period 2016-2020. 
It will only be available online at the BSHP website.
Note that with the completion of digitization of 
both the Pharmaceutical Historian archive and the in-
dexes, hard copies of both will no longer be available 
for purchase.
From volume 47 number 1, published in March 
2017, the Pharmaceutical Historian has been available 
online on an open access basis on the Ingenta Connect 
platform. Th e link to this is http://www.ingentacon-
nect.com/content/bshp/ph No link to the archive or to 
the indexes of past volumes will appear on the Ingenta 
platform.
Transactions of the British Society for the History of 
Pharmacy
As some readers will be aware, in the early years publi-
cation of the Pharmaceutical Historian was accompa-
nied by the occasional appearance of a more scholarly 
publication containing original research articles. Vol-
ume 1 Number 1 of this, under the title Transactions of 
the British Society for the History of Pharmacy, appeared 
in 1970. Number 2 appeared in 1971, Number 3 fol-
lowed 3 years later in 1974, and Number 4 (the last one) 
in 1977. 
We are pleased to report that all four numbers of 
Transactions of the British Society for the History of Phar-
macy have also been digitised, and are again hosted on 
the University of Brauschweig server. For the Transac-
tions the link is https://publikationsserver.tu-braun-
schweig.de/receive/dbbs_mods_65592
Note however that no reference to the Transactions 
will be made on either the ISHP website or on the In-
genta Connect platform as they are a sole publication 
of the British society.  However more details about the 
Transactions and a link to access them online can be 
found on the BSHP website at https://www.bshp.org/
publications/transactions.asp
Newsletters of BSHP and ISHP
Readers may also like to be aware that the entire archive 
of the Newsletter of the International Society for the 
History of Pharmacy, fi rst published in 2000, are also 
available on the ISHP website at https://histpharm.org/
newsletter-archive/ Th e Newsletter of British Society 
for the History of Pharmacy, the BSHP Gazette, fi rst 
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A R T I C L E
Th e emergence of a new concept of 
eff ectiveness: Documentation systems and 




Th e generation of a new concept for assessing the eff ec-
tiveness of psycho-pharmaceuticals in Germany became 
possible as a result of developing new clinical recording 
systems. Drawing on separate debates taking place in 
East and West Germany prior to reunifi cation, this ar-
ticle illustrates how the local development of such sys-
tems entailed extensive semantic changes in the concept 
of eff ectiveness in the treatment of psychiatric illness and 
also generated new concepts of mental health. Similari-
ties and diff erences in the assessment of eff ectiveness are 
described. Both systems generated new concepts of ef-
fectiveness by splitting up, shifting and rearranging old 
classifi cation parameters, resulting in a number of new-
ly described mental states and mental health diseases.
Zusammenfassung 
Das Auftauchen eines neuen Konzeptes zur Wirksam-
keitsbeurteilung von Psychopharmaka in Deutschland 
wurde erst durch die Entwicklung neuer klinischer Auf-
schreibsysteme möglich. Aufbauend auf die unter-
schiedlichen Debatten in Ost- und Westdeutschland vor 
der Wiedervereinigung zeigt der Artikel, wie die lokale 
Entwicklung zweier unterschiedlicher Aufschreibsys-
teme Veränderungen in den Wirksamkeitskonzepten be-
wirkten und darüber hinaus neue Vorstellungen von 
psychischer Gesundheit hervorbrachten. Dabei werden 
Gemeinsamkeiten und Unterschiede in der Wirksam-
keitsbeurteilung beider deutscher Staaten herausgearbe-
itet. Beide Systeme generierten neue Vorstellungen von 
Wirksamkeit indem sie die alten nosologischen Param-
eter aufspalteten, veränderten und neu anordneten und 
damit neue psychische Krankheiten sichtbar machten.
Introduction
In 1958 Professor Hans-Hermann Meyer at the Psy-
chiatrische Universitätsklinik in Heidelberg, one of the 
leading scientists in the fi eld of clinical psycho-phar-
macology in West Germany at that time, summarised 
the results of his research in this fi eld to date as follows:
Th e methods of modern medical statistics fail us 
here. Even studies with matching comparative trial 
series and large numbers show inevitable errors. Th e 
cause of this is diffi  culties in diagnostics, the lack of 
characteristic patho-physiological changes, alternat-
ing processes, spontaneous remissions, and many 
other factors. Comparison to the success stories of 
other clinics, especially from abroad, is all but im-
possible in our fi eld, above all regarding endogenous 
psychoses, due to diverse diagnostics.1
Meyer emphasizes here issues that were to accompany 
the assessment of the eff ectiveness of modern drugs in-
troduced into psychiatry after 1953. Locally diverse di-
agnostic practices in schools of psychiatry, and estab-
lished clinical-descriptive customs in medical 
documentation, made it diffi  cult to capture in a gener-
alisable way the eff ects of psycho-pharmaceuticals.
Th e fact that the particular eff ectiveness of psycho-
pharmaceuticals only became visible with clinical trials 
in patients posed a challenge to their evaluation. Th e 
psychotropic eff ects to be observed, however, are con-
veyed through the subjectiveness of the patients, and 
only become accessible for clinicians in the comments 
of their patients. Drawing on the work of Bruno Latour, 
Philippe Pignarre has argued that in psychiatry the pa-
tient is the only reliable witness to the clinical trial.2 
Th e eff ects of psycho-pharmaceuticals are thus initially 
as diverse as the patients themselves.
Drawing on this insight, I put forward in this arti-
cle the assertion that stabilisation and standardisation 
of psycho-pharmaceutical eff ects only became possible 
with the reassessment of the actual subjective elements 
of the patient’s experience. In my analysis I use the term 
‘witness’ in two senses: on the one hand, I use it to ex-
emplify an early form of eff ectiveness assessment, main-
ly based on the observations of individual physicians as 
witnesses; and on the other hand, I use it to emphasize 
the part played by the patient as the only reliable wit-
ness within the scope of this knowledge generation.
I demonstrate here that generating a robust concept 
of eff ectiveness for psycho-pharmaceuticals was only 
possible due to the development of robust new clinical 
recording systems. Th e development of new recording 
systems took place within the scope of adjusting the 
conditions of a ‘clinical experiment’, as I refer to the in-
troduction of a controlled clinical trial. Within the con-
text of this transformation these new recording systems 
can be regarded as part of experimental systems as de-
scribed by Hans Jörg Rheinberger.3 However, without 
conducting a detailed analysis of this process here, I will 
outline the emergence of a new recording system that 
allows a new concept of eff ectiveness to be developed. 
Th e aim of this investigation is to encourage the local 
development of such systems, which entail extensive 
semantic changes in the concept of eff ectiveness.
https://doi.org/10.24355/dbbs.084-202007291246-0
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Using the example of debates in East and West Ger-
many, I describe the similarities and diff erences in ef-
fectiveness assessment in the two states. Th is approach 
has been chosen because local analyses of German 
standardisation eff orts during the period investigated 
(from 1955 to 1985) hardly ever took account of the fact 
that there existed two diff erent German states. Even 
though the two states shared many traditions – deter-
mined especially during the early stages of introducing 
the new psycho-pharmaceuticals – in the end two dif-
ferent documentation systems were developed. In doing 
so, the debate shifted from local discussions among dif-
ferent schools of psychiatry within the states, to the na-
tional level of “Systemkonkurrenz”, that is, East-West 
competition.
Th is competition was of particular relevance for de-
velopments in East Germany, since West German re-
searchers hardly ever referred to the German Demo-
cratic Republic (GDR). But were the two systems 
suffi  ciently diff erent to provide a diverse range of evi-
dence? And what diff erences actually featured in the 
two systems? Th ough not intended to provide a system-
atic comparison, this article illustrates – based on new 
and additional information – diff erences in the defi ni-
tions of both eff ectiveness and mental health diseases 
that result from taking account of local conditions.
Th is article has four main parts. It begins by de-
scribing the debates in the young West German repub-
lic, which led to the development of the AMP-System, 
constructed by the Working Group on Methodology 
and Documentation in Psychiatry (“Arbeitsgemein-
schaft für Methodik und Dokumentation in der Psy-
chiatrie”).4 Th is is followed by an explanation as to how 
the standardisation of psycho-pharmaceutical eff ects 
was discussed in East Germany and which competing 
positions were confronted and resolved. Th e third part 
outlines the introduction of the AMP system and its 
subsequent development in East Germany. Th e fi nal 
part examines how the new assessment logic of the 
AMP system and its East German extension, the Struc-
tured Psychopathological Assessment System (“Struk-
turiertes Psychopathologisches Erfassungssystem”, 
SPES), led to changes in knowledge and understanding 
about psychotropic eff ects. It is fi rst necessary, however, 
to examine conditions in West Germany in the 1950s 
and 1960s.
Early attempts at the evaluation of eff ectiveness in 
West Germany, 1950s and 1960s
West German attempts in the 1950s and early 1960s to 
assess the eff ectiveness of psycho-pharmaceuticals en-
countered a number of problems: at fi rst, psychiatric 
diagnosis was highly variable and fragmented into 
many locally diff erent schools of thought. Th us the psy-
chiatrist Klaus Conrad considered it bewildering that, 
in West Germany alone, the diagnosis of a specifi c men-
tal health case was allocated to a diff erent category de-
pending on where it was observed.5 During the early 
days of the Federal Republic of Germany (FRG, the 
name used by the communist GDR for West Germany) 
a diagnosis was frequently based on Jaspersian phenom-
enology (an approach which is more concerned with the 
non-mental features of a patient’s illness). Such an ap-
proach did not lend itself to the measurement and 
quantifi cation of the eff ectiveness of individual treat-
ments.
Hence, during the 1950s only vaguely defi nable is-
sues were considered in relation to how the new drugs 
were supposed to improve mental state and how this 
could be measured. A particular German idiosyncrasy 
was that drug eff ects were assessed entirely by individ-
ual physicians.6 In contrast, eff ectiveness assessment in 
the USA made use of state-based systems from an early 
date; test arrangement standards and statistical evalu-
ation in psycho-pharmacology were already well estab-
lished there in the mid-1950s.7
Developments in the United States were carried back 
into the West German debate via German psychiatrists 
such as Fritz Freyhan, who had emigrated to the US dur-
ing the Nazi era and stayed there. At the end of the 
1950s in the journal Der Nervenarzt Freyhan suggested 
that the use of psycho-pharmaceuticals should be orien-
tated around target symptoms. As Freyhan put it:
It is therefore also useless to want to connect the 
therapeutic indications with clinical diagnoses […]. 
For clinical evaluations it thus requires a double 
book-keeping system, that apart from the diagnoses 
also describes the “target symptoms,” the modifi ca-
tion of which is the purpose of the therapy. Only on 
the basis of collected data can psycho-pharmaceuti-
cal modes of eff ectiveness be diff erentiated between 
and can the results of examinations be compared in 
the literature.8
Freyhan’s request, however, was a far cry from West 
German reality, where the eff ectiveness of new drugs 
was largely collected and evaluated by reference to clin-
ical diagnoses in individual case histories. Closely fol-
lowing this pattern, the published success stories of psy-
cho-pharmaceuticals at that time were often made 
plausible by the use of casuistics, i.e. the reasoning used 
to resolve moral problems by extracting or extending 
theoretical rules from particular instances, and apply-
ing them to new instances. In doing so, those case his-
tories were closely linked to the documentation found 
https://doi.org/10.24355/dbbs.084-202007291246-0
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in the patient fi les, and usually partially copied verba-
tim from them.9
Publications arguing with published statistics were 
almost non-existent in West Germany during the 
1950s. Likewise, placebo-controlled double-blind trials 
were virtually unheard of before the late 1960s. Clini-
cians rejected them, arguing that they themselves were 
perfectly capable of evaluating positive drug eff ects 
with corresponding tests.10 But eventually evaluation 
attempts described in the literature were discussed in 
psychiatric clinics. However, in the 1950s evaluations 
were primarily based on the impression of the exam-
iner, and were closely attached to the testimonial of the 
physician; they were thus subject to individual fl uctua-
tions and bias.
But in the late 1950s fi ve young German clinicians 
criticised the fact that data collected in this way varied 
too much from clinic to clinic, and was barely compa-
rable at either the national or international level. Th ey 
founded a Society for Neuropsychopharmacology (“Ar-
beits-gemeinschaft für Neuropsychopharmakologie”, 
AGNP) and dedicated their work to the standardisation 
of eff ectiveness of mental health treatments. In later 
years the membership of AGNP would include psychi-
atrists, pharmacologists and pharmaceutical industry 
staff . It also provided the national selection committee 
for the International College for Psychopharmacology 
(“Collegium Inter-nationale Psychopharmacologicum”, 
CINP).
Th e ‘Club of Five’ and the AMP System in West Ger-
many in the 1960s 
During the early 1960s a so-called ‘Club of Five’, con-
sisting of the psychiatrists Hanns Hippius (born 1925), 
Max P. Engelmeier (1921-1993), Walter Schmitt (born 
1920), Kurt Heinrich (1925-2015), and Dieter Bente 
(1921-1983), decided to develop a robust and compre-
hensive recording system. Such a system would harmo-
nise the highly varied use of psycho-pharmaceuticals 
across the nation, contribute to methodical standardi-
sation of clinical testing procedures, and generate a val-
id and reliable concept of eff ectiveness.
However, psychiatry schools in West Germany at 
that time gave priority to individual factors, placing 
emphasis on understanding the patient’s psychological 
makeup, as well as on the face-to-face encounter be-
tween the patient and the patient’s physician.11 Even the 
psychiatrists from the Club of Five assigned themselves 
to diff erent schools of thought in psychiatry, ranging 
from Dasein analysis (an approach based on the exis-
tential philosophy of Martin Heidegger) to biochemis-
try. But how could all these divergent observations 
based upon completely diff erent premises be standard-
ised? In the end, the Club of Five concluded that this 
was only possible by a total restructuring of practice. 
According to these researchers the evaluation of eff ec-
tiveness necessitated the collection of a vast amount of 
information:
Primarily the imperative [is] to collect possibly nu-
merous individual data from clinical trials; because 
only by embarking upon this methodical path would 
consistencies and divergences, the essential and the 
irrelevant, as well as indications and contra-indica-
tions, later reveal themselves.12
To meet this goal it would be necessary to change the 
existing large number of very small, structured clinical 
trials into the controlled conditions of a large experi-
ment. Th is transformation marked the starting point 
for a reorganisation of knowledge. In the clinic too 
practice increasingly changed to statistical experimen-
tal conditions. As a fi rst step this required the transla-
tion of descriptive clinical reports of the psycho-phar-
maceutical eff ects of various treatments into statistical 
parameters using standardised forms of collection.13
For the standardised assessment of psycho-pharma-
ceuticals the fi ve psychiatrists developed medical docu-
mentation in the form of a diagnostic card, which was 
attached to each patient’s fi le and formed part of the 
clinical survey. Th e documentation was meant to be 
atheoretical, so as to allow psychiatrists trained in any 
school of thought to accept it. Th e diagnostic card sam-
pled 114 somatic and 110 psycho-pathological features 
in a formalized way, thus providing a quantifi able start-
ing base for statistical evaluation (Figure 1).
Th e fi ve psychiatrists explained that at the core of 
their venture was the complete symptomatic decoding 
of a mental health statement. Th is was supposed to re-
place the previously existing alignment to complex bio-
graphical case histories in medical documentation. 
However, the psychiatrists did not explain how they 
generated the individual symptoms; they themselves 
conceded that the collected symptoms were dispropor-
tionately harder to scale reliably than were exactly 
measurable quantities in a natural scientifi c experi-
ment.14 Th e new form of collection was supposed to al-
low the subjectiveness of the physician and patient to 
be removed from consideration, and to create a reliable 
concept of eff ectiveness.
In the late 1960s the diagnostic card fi nally gained 
acceptance in West Germany as binding medical docu-
mentation, despite severe criticism by some clinicians 
on this symptom-orientated form of collection. During 
its initial establishment period, at least, the card met 
with several forms of resistance. Some psychiatrists, for 
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Figure 1. AMP-System (Source: Schmitt, W. Psychiatrische Pharmakotherapie. Experiment und klinische Grundlagen 
eines Klassifi zierungsversuches. Heidelberg: Dr. Alfred Hüthig, 1965. Th eoretische und klinische Medizin in Einzel-
darstellungen. Bd.21, S.57)
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instance, did not consider the introduction of new 
measurement methods to be an adequate way to gener-
ate knowledge within psychiatry.15 Also criticised was 
the disappearance of the physician-patient relationship 
from the eff ectiveness evaluation. Explaining the eff ects 
of the drug merely from the eff ect of a substance would, 
it was argued, nurture a position in which the patient 
would become more and more irrelevant.16
However, such reservations were closely linked to 
criticisms against the earlier diagnostic system of Emil 
Kraepelin. Th e new AMP system reminded some re-
searchers of Kraepelin’s system, although it was becom-
ing increasingly marginal. After 1965 the diagnostic 
card was developed further in collaboration with Swiss 
scientists, and it was relaunched in 1969 under its ini-
tials as the ‘AMP system’.17 In the early 1970s the sys-
tem was published for the fi rst time as a manual for the 
documentation of psychiatric evidence.18
To this day the system remains in use in several re-
vised forms as an important means of documenting 
psychiatric evidence in Germany.19 However, with this 
new form of knowledge collection the documented con-
cept of eff ectiveness itself also changed. Before these 
changes are analysed in more detail, I will provide a re-
construction of methods of eff ectiveness standardisa-
tion in East Germany at this time in order to provide a 
broader perspective.
Eff ectiveness standardisation in East Germany until 
the 1960s
In May 1962 Karl Leonhard, an internationally re-
nowned psychopathologist and professor at the Charité 
University Hospital in Berlin – then the capital of the 
German Democratic Republic – received a letter from 
the USA. In this letter an American psychiatrist in-
quired how Leonhard planned to combine his diff eren-
tiated psychopathology with the newer somatic treat-
ment methods, especially psychotropic drugs. Leonhard 
replied as follows:
1. [...] I draw a sharp distinction between psychoses 
that clear up under all circumstances even with-
out treatment and those that are subject to some 
damage or defect […]. With cycloid patients a 
somatic treatment accelerates the success; with 
the unsystematic schizophrenias it can in my 
opinion often prevent damage. […]
2. With the systematic forms, in my opinion, all 
treatment forms are futile. At best they will alle-
viate the condition short-term, but the process 
continues independent of treatment. […] I have 
not observed with any certainty that any one of 
the various [somatic treatment] options would be 
signifi cantly more successful than the other.20
Th is quotation makes clear that Leonhard attached the 
highest priority to the exact diagnosis of somatic and 
psychiatric conditions and description of psycho-phar-
macological therapies. He devised his own classifi cation 
system, and in later years he and his students made 
great eff orts to standardise the eff ectiveness of new psy-
cho-pharmaceuticals using this eponymous Leonhard-
ian classifi cation system. In the 1950s and 1960s this 
was one of the most infl uential standardisations of ef-
fectiveness in East German psychiatry.
Central to Leonhard’s psycho-pathology was the 
very fi ne, precise classifi cation of psychoses according 
to illness progression and prognosis. Long-term obser-
vation, often over the course of decades, played a central 
role in the knowledge regime of the Berlin clinic. Le-
onhard had developed his system for diagnostic descrip-
tion in the tradition of Karl Kleist. Th is system diff er-
entiated disease entities into numerous, separate 
sub-groups. Leonhard’s method of diagnosis was 
marked by a rigid demarcation between diff erent dis-
ease entities, to which he ascribed the highest priority. 
Th is kind of psychiatric classifi cation formed some-
thing that, in the history of psychiatry, has been de-
scribed as the School of Splitters.
Leonhard’s approach to the standardisation of the 
new psycho-pharmaceuticals was widely adopted 
throughout East Germany, largely due to the eff orts of 
his students. Above all, Heinz A. F. Schulze, the lead-
ing senior physician at the clinic, distinguished himself 
in the fi eld of psycho-pharmaceutical research. Th e par-
ticular research focus of the clinic – the precise diff er-
entiation of psychoses – is also refl ected in Schulze’s 
publications on psycho-pharmaceuticals. In the 1960s 
Schulze and his colleagues published several articles on 
the standardisation of eff ectiveness using Leonhard’s 
diagnostic system.21
Two aspects were decisive for those publications. 
Firstly, Schulze and his colleague Neumann wanted to 
know more about the drug – that is, its specifi c indica-
tion in accordance with Leonhard’s psycho-pathology. 
Secondly, they employed the drug as a tool in the dif-
ferentiation of psycho-pathological states. Th ey used 
the eff ects of the psycho-pharmaceuticals in order to 
better separate given disease states from each other. In 
order to make their eff ects plausible they made use of 
casuistics with their arguments, just as their West Ger-
man colleagues had done in the 1950s.
Th eir focus was the individual. Th ey took the un-
derlying case histories, often verbatim from the indi-
vidual patient’s fi les. Th ey argued that individual cases 
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could be considered as typical examples, and hence gen-
eralisations could be made about underlying disease 
states. In doing so they drew upon that same evidence 
for the systematic classifi cation of psychiatric diseases 
which in West Germany had already been rejected in 
the early 1960s.
Even in East Germany Leonhard’s model was not 
without controversy. But his fi ercest adversary during 
the 1960s, Hellmut Rennert, who held a chair in Halle, 
southern Germany, also tried to standardise the eff ec-
tiveness of the new psycho-pharmaceuticals by means 
of his pathology. Rennert used the new drugs to estab-
lish his own doctrine of the universal genesis of psycho-
ses.
Rennert’s basic idea contradicted Leonhard’s par-
ticular classifi cation scheme. He criticized other ap-
proaches such as Leonhard’s for putting too much em-
phasis on individual pathogenetic aspects. Renner’s 
ideas, however, were based on the idea of “Einheit-
spsychosen” – the belief that the various forms of psy-
choses that appeared could be understood as nothing 
more than diff erent stages in the same process of ill-
ness development. Rennert’s students, and Gert-Eber-
hardt Kühne in particular, tried to support this theo-
ry by psycho-pharmaceutical therapy. They 
demonstrated that psycho-pharmaceuticals did not 
work for the individual disease entities of Leonhard’s 
classifi cation schemes, but only for syndromes.22 Le-
onhard’s desire to standardise the application of psy-
cho-pharmaceuticals with the help of his doctrine of 
psychosis was common amongst East Germany psy-
chiatrists.
Developments in East Germany in the 1960s and 
1970s 
Th ings began to change in East Germany in the late 
1960s. Ehrig Lange, a professor of psychiatry and psy-
chotherapy in Dresden, published an account of an ef-
fectiveness study on the uses of haloperidol and trifl u-
peridol in 1968. The Dresden clinic had been 
commissioned to conduct the study by the pharmaceu-
tical company Janssen, in cooperation with West Ger-
man clinics.23
 In another article published in the early 1970s 
Lange and his colleagues called for a new orientation 
in East German psycho-pharmaceutical therapy. Th e 
Dresden researchers argued that a new form of eff ec-
tiveness understanding must be employed in order to 
solve the problems. A new system of evaluating the ef-
fectiveness of psycho-pharmaceuticals must be
connected with the measurability and the specifi ca-
tion of psychiatric phenomena as well as the quanti-
fi cation of various forms of [clinical] courses; since a 
process according to the old traditional method of 
subjective-descriptive understanding of psychiatric 
disorders without the possibility of statistically analyz-
able comparison is, in the future with the testing of 
psycho-pharmaceuticals as well, no longer viable.24
Th e authors called for a standardized system of docu-
mentation through target symptoms that could also be 
evaluated electronically. Th ey used the AMP system 
developed by the West German psychiatrists, and ad-
vised other clinicians to do the same.25 A glance at the 
subsequent discussions on the standardized evaluation 
of psychiatric drugs makes clear that the debate was 
concentrated on the electronic processing of data, in ef-
fect profi les that could be comprehended statistically.26
In the states of the Eastern bloc of the USSR too, 
statistics and symptom-orientated evaluation were fi -
nally coming to the foreground. Th e famous Czech psy-
cho-pharmacologist Oldrich Vinar summarized the 
confl ict between the school advocating the old psycho-
pathology-oriented approach of effi  cacy assessment and 
those favouring a symptom-oriented evaluation in his 
comments at a nationwide conference on psychotropic 
therapy held in East Berlin in May 1972:
Basically our approach is to avoid nosological-diag-
nostic considerations because we do not label the 
criteria for the patients’ sample as diagnostics. We 
use temporary provocative names like chlorproma-
zine affi  n[ity] or aminitryptilin affi  n[ity] psychosis. 
If in doing so we will fi nd groups of diseases with a 
common pathogenesis in the end, we might come 
to nosological diagnoses again.27
Did this mean the fi nal renunciation of a belief in mak-
ing psychiatric diagnoses based on a system of nosology 
(the classifi cation of diseases) derived from patient de-
scriptions? Had East German researchers only adopted 
the West German AMP system rather than developed 
their own? Taking a closer look at further developments 
in East Germany allows us to prove that this was by no 
means the case. In the 1970s one of Rennert’s students, 
Gerhard-Eberhardt Kühne, continued to work on a 
syndrome-oriented medical documentation. Since the 
1960s Kühne had rejected a strict alignment to nosolog-
ical systems, demanding instead an assessment geared 
to statistical parameters.28
In 1970 a multi-clinical working group of the Re-
search Department at the Dresden VEB drug factory 
(“Arzneimittelwerk”) was established. Its purpose was 
to establish systematic clinical cooperation in the fi eld 
of psycho-pharmacology. Kühne himself was responsi-
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ble for the development of new documentation proce-
dures.29 One of the objectives of the working group was 
to develop an individual clinical documentation sys-
tem, which could be used for investigative research in 
psycho-pharmacology.30
Th is research priority on psychiatric medical docu-
mentation was funded by the East German Depart-
ment of Health (“Ministerium für Gesundheitswesen”) 
and this eventually led to the development of a unique 
system.31 We can, however, only speculate about why 
the AMP system was no longer applied in East Germa-
ny, and why health system offi  cials instead suggested 
the elaboration of a distinct and separate medical doc-
umentation system.
In view of the variety of problems East German psy-
chiatry faced during this era, this research priority rath-
er comes as a surprise, especially since in many respects 
the two systems were quite similar. One feasible expla-
nation is the increasing imperative in East German psy-
chiatry to be distinguished from the ideologically chal-
lenging concept of the capitalist West after 1971.32 Th e 
pressure for such distinction was accompanied by a de-
mand to develop a separate and idiosyncratic East Ger-
man research agenda.
Kühne and the Structured Psychopathological As-
sessment System (SPES) in East Germany
Th e development of a proper medical documentation 
system can certainly be attributed to this logic. In any 
case it can be stated that Kühne worked for the entire-
ty of the 1970s on the development of the system. In 
the late 1970s he fi nally presented the results of his re-
search on the evaluation of the eff ectiveness of new psy-
cho-pharmaceuticals. He presented an entirely new re-
cording system, which he called the ‘Structured 
Psychopathological Assessment System’ (SPES) which 
had been developed by the working group.33
In 1983 Kühne published the complete manual for 
the fi rst time. In his foreword he emphasized that the 
genesis of new measuring instruments in psychiatry 
had reached a new dimension with the introduction of 
modern psycho-pharmaceuticals. Concerning the need 
for a distinct and idiosyncratic system he explained:
Th e development of psychometric procedures in 
psychiatry was and remains to be therapy-oriented. 
Moreover the inclusion of mathematical and statis-
tical methods as well as electronic data processing 
increasingly allowed the investigation of the struc-
ture of psycho-pathological syndromes and the clas-
sifi cation of mental diseases. Th ese studies are re-
quired to make a qualified evaluation of the 
conditions causing and developing psychonerval dis-
orders possible by means of a growing number of 
results from basic research.34 
Closely following Freyhan’s postulate of double 
book-keeping, Kühne regarded his syndrome-oriented 
assessment as the synthesis of two things; a symptom-
orientated documentation of fi ndings (like the AMP 
system) and nosological systems (such as that developed 
by Leonhard). Using his own assessment system, how-
ever, now permitted ‘simple book-keeping’, and, he not-
ed that ‘syndrome-genetic examinations – without pre-
judging clinical-empirically founded nosological 
groupings – allowed more comprehensive statements 
regarding aetio-pathogenetic mechanisms.’35 Th us it 
was Kühne’s declared goal to release assessment from a 
purely descriptive narrative, and achieve with his sys-
tem a new form of research on the causes of mental dis-
orders. In doing so he strove to visualize genetic, con-
stitutional and psychosocial factors based on syndrome 
assessment.36
We must bear in mind here that East German psy-
chiatry principally acted on the assumption of the bio-
logical foundation of mental disorders. Such disorders 
would not emerge until specifi c environmental condi-
tions prevailed, but they originated ultimately in the 
subject’s genetic predisposition.37 By the late 1960s a 
symposium entitled “Socialism, science-technical Rev-
olution and Medicine”, organized by the East German 
Health Department, had already emphasized that the 
genetic screening of the population was a signifi cant 
component of prophylaxis.38 Th e widespread expansion 
of genetic counselling agencies since 1970 shows how 
consistently these eff orts were realized.39 Kühne’s sys-
tem itself arose, among other things, from a research 
priority on the investigation of neurobiological-based 
mental disorders.40
But what exactly did Kühne’s system look like? His 
medical documentation consisted of two sub-systems, 
the SPES-A and the SPES-B. SPES-A concerned a non-
nosological geared, symptom-oriented collection sys-
tem, which was basically intended for investigative psy-
cho-pharmacological research.41 Kühne explained that, 
in addition, the SPES-A qualifi ed for follow-up studies 
and epidemiological issues, owing to its relative univer-
sality regarding psychopathological facts and circum-
stances;42 whereas another part of the medical documen-
tation, the SPES-B, was basically syndrome- oriented, 
and represented a further development of the SPES-A.
Th e underlying syndromes were generated from a 
factor analysis with 400 SPES-A examined psychotics. 
SPES-B was essentially meant to facilitate the standard-
ised collection of the psychopathological fi ndings of 
cross-sectional and follow-up studies in psychotic in-
https://doi.org/10.24355/dbbs.084-202007291246-0
 PHARMACEUTICAL HISTORIAN  ·  2018  ·  Volume 48/2 37
Figure 2. SPES-System front page (Source: Kühne, Gert-Eberhard and Grünes, Jörn Uwe. Das strukturierte psycho-
pathologische Erfassungs-System (SPES): Ein Beitrag zur standardisierten und dokumentationsgerechten psychopatholo-
gischen Befunderhebung. Leipzig: Th ieme, 1983. Beiträge zur klinischen Neurologie und Psychiatrie. Bd 51, Appendix)
https://doi.org/10.24355/dbbs.084-202007291246-0
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Figure 3. SPES-System back page (Source: Kühne, Gert-Eberhard and Grünes, Jörn Uwe. Das strukturierte psychopa-
thologische Erfassungs-System (SPES): Ein Beitrag zur standardisierten und dokumentationsgerechten psychopathologis-
chen Befunderhebung. Leipzig: Th ieme, 1983. Beiträge zur klinischen Neurologie und Psychiatrie. Bd 51, Appendix)
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patients.43 Th is system was (among other things) also 
aimed at epidemiological research, by being able to fa-
cilitate systematic studies of selected syndromes.
Due to the close interconnection of his two psycho-
pathological forms of medical documentation Kühne 
tightly attached symptom-oriented psycho-pharmaco-
logical research to the development of new syndromes. 
David Healy has found that over a period of time psy-
cho-pharmaceutical research has dissociated itself from 
quantitative gradual symptom-oriented collection sys-
tems in order to turn to more categorical forms of col-
lection.44 Th ese would facilitate the tracking down of 
new outlets for psycho-pharmaceuticals. Hence Küh-
ne’s system enabled the transfer out of the symptom-
orientated classifi cation into broader syndromes gener-
ated out of the individual symptoms, approaching the 
categorisation postulated by Healy.
From verbose forms of symptom gathering to word-
less objectivity
But what were the eff ects of such new forms of medical 
documentation, and how did they change the concept 
of eff ectiveness? Th e two kinds of medical documenta-
tion examined here describe the attempts of psychia-
trists from diff erent schools of thought to standardise 
the eff ects of psycho-pharmaceuticals. However the 
conditions connected to the creation of these new sys-
tems of documentation were also incorporated into the 
newly emerging concept of eff ectiveness.
Th ese changes necessitated crucial adjustments. Th e 
transformation into a scalable and dimensional system 
was on the one hand supposed to facilitate the measur-
ability of symptoms; yet on the other hand this restate-
ment helped to achieve an opening up of the potential 
indications for psycho-pharmaceuticals. Th is now al-
lowed for instance, treating symptoms labelled as ab-
normal, isolated, hypochondriac, anxious and agitated 
in combination with each other and psycho-pharmaco-
logically, even if they could not yet be assigned to an 
existing classifi cation system.
While previously the categorical diagnoses off ered 
little space for the subtle eff ects of a drug, defragmen-
tation into individual symptoms now off ered new pos-
sibilities for the organisation of disease categories. 
Along these lines both the West German AMP system 
and the East German SPES performed the crucial func-
tion that a recording system fulfi ls within a research 
system, that is, both systems had to advance the stabil-
ity and reproducibility of the individual elements.
Yet at the same time they were intended to produce 
diff erences in terms of research systems and to facilitate 
the search for new questions. It was only with this ex-
tension to the remit that adjustment of psychiatric di-
agnoses to the eff ects of drugs was eventually enabled. 
Th us Healy’s thesis (that in order to develop new psy-
cho-pharmaceuticals, psycho-pharmacology had to dis-
card quantitative, gradual, purely symptom-orientated 
collection systems and embrace categorical assessments) 
can be historically specifi ed.45
Investigation into the development of the AMP sys-
tem has shown that it was not until the transformation 
of a categorical order (as represented by nosological sys-
tems) into a symptom-oriented system that this realign-
ment of an eff ectiveness concept was made possible in 
West Germany. As indicated earlier with the develop-
ment of SPES in East Germany, researchers there acted 
on this symptom-orientation, yet developed the system 
further in a syndrome-oriented direction. In doing so, 
they re-approximated clinical-nosological and symp-
tom-oriented research systems, thus also visualising 
new disease groups.
Th us the West German AMP system and its East 
German development, the SPES, fulfi lled a double task: 
on the one hand they depicted new effi  cient profi les, 
and standardised the eff ectiveness of psycho-pharma-
ceuticals; on the other hand they visualised new psy-
cho-pathological categories. In particular, the SPES 
would facilitate new forms of epidemiological research 
and a reinvigoration of aethio-pathogenesis. Th is can 
be attributed (amongst other things) to the fact that – 
in the state-controlled East German health system – 
epidemiology achieved major importance. As early as 
the mid-1960s the East German Health Department 
had pointed out that epidemiological research was one 
of psychiatry’s major tasks.46
Yet in spite of several research eff orts, the desired 
state of research was not achieved during the following 
20 years. In the mid-1980s the Health Department 
considered that national epidemiological research was 
still behind international standards and re-issued re-
search programmes. Th e research focus on biological 
foundations of endogenous psychoses led by Kühne in-
cluded a major project on the epidemiology of endog-
enous psychoses.47 In the international arena Kühne 
was also regarded as an expert in psychiatric epidemi-
ology. Hence it can be assumed that Kühne strength-
ened research, especially by applying his own system.
But what were the eff ects of applying the two re-
cording systems on patients? How did it change their 
roles as reliable witnesses, whose statements are essen-
tial elements in ensuring the visibility of medication 
eff ects? It should be stated that the systems not only 
standardised psychiatric compilation, but also subject-
ed patients to a normed objectifi ed interrogation.
Th us the translation of the eff ectiveness assessment 
in the new systems required that not only the psychiat-
ric diagnosis, but also the patient’s behaviour, be tran-
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scribed into a series of symptoms. Transferring the pa-
tient’s narrative into the new recording systems entailed 
the translation of the anamnesis and biographical re-
port of psychiatric exploration into a series of quantifi -
able units. Lorraine Daston described such an abstrac-
tion from the language of the patient and its adaption 
to mechanically evaluable terms as a new form of ob-
jectifi cation, which she called ‘wordless objectivity’.48
According to Daston, dissociation from the clini-
cian’s words – and also, I would suggest, from those of 
the patient – in doing so were characteristic of a new 
epistemological form, in which phenomena were meant 
to speak for themselves. While patients’ experiences 
were still discernible, at least in traces, in verbose ex-
ploration or published case histories, assessing knowl-
edge by means of the new systems required further ab-
stractions from the patients’ language.
Patient experiences had to be further fi ltered by psy-
chiatrists so as to be able to eventually reduce the state-
ments to symptoms. In the end the patient as ‘reliable 
witness’ disappeared in those symptom-oriented forms 
of collection. Within the scope of this process of ab-
straction psychiatric patients turn into case studies in 
quite a peculiar way. By subjecting them to observation 
and interrogation, measurable in quantifi able units, 
they are at the same time put through a disciplining 
standardisation.49 Eff ects, which previously seemed to 
be uncontrollable, were supposed to become manage-
able with this subdivision of the patient, which is inher-
ent in this standardisation.
Conclusion
In this article I have described the emergence of diff er-
ent schools of thought regarding the diagnosis of psy-
chiatric disease and the assessment of psycho-pharma-
ceuticals in East and West Germany during the period 
1955 to 1985. Whilst in West Germany the assessment 
of psycho-pharmacological eff ects became disengaged 
from casuistic collection around 1960, it took about a 
decade longer in East Germany. Th e fact that East Ger-
many started to use objectifi able medical documenta-
tion relatively late is quite remarkable, given that the 
standardisation of medicament-related eff ects had been 
a major subject in East Germany as early as the 1950s 
and 1960s. Hence the late introduction of symptom-
oriented medical documentation can probably be at-
tributed to the power of elder and more conservative 
psychiatry professors, who gained a great deal of infl u-
ence on the development of the national health system 
in the aftermath of the exodus of doctors (“Ärzte-
fl ucht”) from East Germany.
With the political realignment to a socialist psychi-
atry, individual research systems also gained new mo-
mentum. It must remain an open question, however, 
whether the SPES can be regarded as a very specifi c 
form coming from a socialist state, despite its funding 
from the East German Health Department, or if it is 
not simply another local tradition of eff ectiveness 
standardisation. More appealing for the SPES interpre-
tation is the fact that Gerhard-Eberhard Kühne’s re-
search focussed on the fi elds of psycho-pharmacology 
and psychiatric epidemiology, and that he planned to 
connect both areas with each other in his medical doc-
umentation.
As I have shown in this article, both research sys-
tems generated a new concept of eff ectiveness by split-
ting up, shifting and rearranging the old parameters for 
the classifi cation of psychiatric illness, thus visualising 
‘new’ mental diseases. In doing so, they set off  the emer-
gence of a new concept of eff ectiveness, dissociated 
from its original meaning. Th us, the newly generated 
concept of ‘wordless objectivity’ allowed psychiatry to 
create a robust concept of eff ectiveness. But it also had 
its drawbacks, because it had become largely detached 
from the eff ects experienced by the patients.
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Kohl: an ophthalmic dosage form in 
Persian medicine, 1555 to 1853
Samaneh Soleymani and Arman Zargaran
Abstract
Early Persian pharmacopeias, known as Qarābādins, 
contained a large number of pharmaceutical dosage 
forms which included many ophthalmic preparations. 
One of the most commonly used ophthalmic formulas 
was known as Kohl. It was prescribed for eye protec-
tion, visual strengthening and for the treatment of eye 
diseases such as pterygium, trachoma, itchy eyes and 
leukocoria. It has also been extensively used as a cos-
metic from ancient times up to the present day. Th is 
article presents an investigation into the diff erent types 
of kohl formulation, along with their components and 
uses, which have formed the basis of the most com-
monly used Qarābādins in Persian medicine.
Abstract in Iranian 
Introduction
Although it is usually agreed that in Europe the process 
by which pharmacy formally separated from medicine 
began in 1231 AD with the Edict of Palermo1 the sep-
aration of pharmacy from medicine in Persian dates 
back to antiquity.2 Th ere are several pharmacopeias or 
pharmaceutical encyclopedias (called Qarābādin in 
Persian medicine) written by pharmacist-physicians. 
Th ese books describe diff erent types of pharmaceutical 
dosage forms, along with methods of how to prepare 
them, and also list various prescriptions and methods 
of administration. Th e formulas include a range of oph-
thalmic dosage forms.3 4 Th e most popular ophthalmic 
formulas are those containing kohl (Ek-hal), ophthal-
mic dusting powders (Zaroor), ophthalmic supposito-
ries (Shiaf ), eye washes (Ghasool), eye drops (Ghotoor) 
and eye cooling preparations (Barood).5 6
Kohl (also known as Surma) is a solid dosage form 
which is usually black in colour. It has been adminis-
trated for the prophylaxis as well as treatment of diff er-
ent eye diseases and also as a cosmetic since antiquity.7 
Indeed, it is still used as a cosmetic today. Because of 
the importance of kohl as one of the most common 
ophthalmic formulations used in the prevention and 
treatment of a wide range of eye diseases by Persian 
practitioners the study reported here was designed to 
investigate the diff erent types of kohl dosage form in 
several of the Qarābādin pharmaceutical textbooks 
used in Persian medicine.
Qarābādins, traditional pharmaceutical encyclope-
dias
Qarābādins are traditional Persian pharmacopeias that 
mainly consisted of a range of multi-ingredient prod-
ucts which included herbal, mineral, and animal med-
icines. Preparation routes, dosage forms, clinical pro-
cesses and other associated aspects – as well as diff erent 
clinical approaches to the use of natural medicaments 
– are described in Qarābādins.8 Th ese books were writ-
ten with a variety of text structures and patterns.9 One 
example of such pharmacopeias is the Qarābādin-e-
Shafai, written by Mozafar Shafai Isfahani in 1555 AD. 
Th is is a valuable resource which provides a useful sum-
mary of dosage forms and pharmaceutical aspects.10
Other examples include the Qarābādins-e-Ghāderi 
written by Hakim Arzani in 1714 AD. Th is presents 
information based on anatomy and is arranged from 
head to toe for diff erent diseases.11 Th e Qarābādin-e-
Salehi, written by Ghaeni Heravi in 1766 AD, was a 
famous pharmacopeia which includes more than 200 
pharmaceutical formulas arranged in alphabetical or-
der.12 Th e Qarābādin-e-Kabir, written by Aghili Kho-
rasani Shirazi in 1772 AD, is a more comprehensive 
pharmacopeia in which preparations are classifi ed al-
phabetically on the basis of a chief component.13 Final-
ly, the Qarābādin-e-Azam, written by Hakim Azam 
Khān in 1853 AD, is arranged predominantly accord-
ing to the alphabetical order of the various dosage 
forms.14 Figure 1 illustrates the page on a type of kohl 
(without Ithmid ) of Aghili Khorasani Shirazi’s 
Qarābādin-e-Kabir, written in 1772.
Kohl: description and historical background 
Kohl has been defi ned as a dry eye ultra-fi ne powder 
encompassing one or more ingredients – such as lead 
sulphide, gemstones, minerals and herbs – that were 
used in the eyes or on the eyelids by means of an eye 
stick.15, 16 According to the Qarābādin books the inven-
tor of kohl was Hippocrates.17 But historical evidence 
shows that the use of kohl goes back to the Bronze Age, 
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Figure 1. Page on a type of kohl (without Ithmid) of Aghi-
li Khorasani Shirazi’s Qarābādin-e-Kabir, written in 
1772.
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around 1100-3500 BC.18 Historical documents illus-
trate the application of eyeliner around the eyelids in 
ancient Egyptians for its protective eff ect against the 
glare of the sun.19 From the grave paintings of the Old 
Kingdom (Th e Age of Pyramids, 2900-2240 BC) to the 
surprising portraits of the Roman Occupation, kohl 
recipes were transfered from one generation to another 
over the centuries.20, 21 Kohl was one of the ophthalmic 
pharmaceutical preparations applied in Persia at least 
from 500 BC.22
Th ere were two categories of kohl mentioned in 
Qarābādins; one category contained Ithmid (or Ismad) 
as its main component, while the other did not. Ithmid 
was composed only of galena (lead sulphide) that was 
found in a lead mineral in Isfahan (a province and city 
in the centre of Iran) where it was called Ithmid-e-Isfa-
hani (or Surma-e- Isfahani).23
In addition to Surma stone or Ithmid, other me-
dicinally active ingredients such as gemstones (ruby, 
garnet, emerald, turquoise, opal), marine coelenterates 
(coral, pearls), minerals (gold, silver, zinc oxide, copper 
oxide, plumbum oxidum),24 and medicinal herbs 
(Foeniculum vulgare Mill. extract, Crocus sativus L., Pip-
er longum L., Piper nigrum L., and Chelidonium majus 
L.) were used in kohl formulations.25
Some special ingredients such as musk were blend-
ed with the chief components to give it a particular in-
demnity and to help identify the supplier.26 Musk deer 
(Moschus spp.) was a form of animal medicine that was 
an important component of Persian medicine. Its anti-
histaminic and anti-infl ammatory activities are report-
ed in animal models.27 Some of the kohl formulations 
described in Qarābādins are presented in Table 1.
Considerations in formulating kohl preparations
Ingredients used in kohl dosage forms needed to be 
completely milled and passed through the fi nest sieves. 
Reduction of particle size was required to prevent prob-
able injuries to the eye and to facilitate the penetration 
of remedies deep into the eye.28 Th ey should have been 
dried in the shade and protected from excessive water 
and dust. Minerals, stones and sea shells required par-
ticular modifi cations or processing (a process named 
Tadabir). Th is might entail a decrease in particle size, 
in burning (Ehragh) or washing (Taghsil).29 Burning of 
the ingredients was a method of reducing their particle 
size and also of preventing bacterial growth and con-
tamination.30 In several cases the components were ex-
posed to fi re and not burnt completely.31
In the washing process the materials should have 
been completely immersed in a liquid; the sediment cre-
ated was then separated from the liquid phase above 
and dried. If necessary this process was repeated a few 
times.32 To prolong its shelf life, to maximize its eff ec-
tiveness, and to prevent the penetration of air the kohl 
formulation was kept in a glass container and was tight-
ly sealed with wax.33 Kohl was used in the eyes or eye-
lids and administered by means of an eye stick.34 Th e 
material used to make the eye stick varied according to 
the ophthalmic disease being treated. It was common-
ly made from gold, silver, lead or a very soft barberry 
root.35, 36
Th erapeutic and cosmetic value 
Kohl was the most frequently prescribed eye product in 
Persian medicine for the strengthening and mainte-
nance of eye health, and also for improving vision. Also, 
it was used for the prevention and treatment of various 
eye disorders including pterygium (Nakhoneh or Nak-
honak), trachoma (Sabal) and itchy eyes (Hekkeh). It 
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was also used for the treatment of eyes that were per-
manently moist, or sometimes for the lachrymation 
that is seen in a disease like glaucoma (Dameè). Other 
eye conditions in which it was used included the whit-
ening of the eye’s pupil or leukocoria, which is now 
known to be caused by cataract, conjunctivitis and ret-
inoblastoma (Bayaz).37, 38, 39, 40, 41
Current investigations support the probable positive 
eff ects of many of the ingredients used in the kohl for-
mulations. Zinc oxide (Tutiya) was possibly included in 
kohl because of its strong natural sun blocking prop-
erty. Th is would probably strengthen the protective 
ability of lead sulphide against the sun’s glare,42 and also 
illustrates kohl’s cosmetic application.
 Extract of F. vulgare (Badiyan) was usually used in 
the processing of Kohl stone (Ithmid ). C. majus 
(Mamiran) exhibits an extensive spectrum of biological 
activities including anti-infl ammatory, anti-microbial, 
anti-tumour and analgesic actions that support some of 
its eye-regenerative eff ects.43 According to Avicenna’s 
Canon of Medicine44 C. sativus (Za’faran) was used for 
eye diseases such as lacrimation, painful eye, cataract, 
pterygium, purulent eye infection and poor vision.45 
Studies have shown that crocetin in saff ron have pro-
tective eff ects against retinal damage and macular de-
generation that is one of the causes of blindness.46 Pip-
er longum (Dārfelfel) was extensively in the kohl 
formulations and is a herb that has shown considerable 
potential for use in ocular diseases.47
Today there are worries about the presence of lead 
sulphide in the kohl formulation and the possibility of 
toxicity with it, but several animal and human studies 
have demonstrated that lead in the kohl formulations 
is not absorbed through the trans-corneal route, and 
that kohl is not responsible for any enhanced blood lead 
concentration. Of course, during pregnancy, its con-
Categories Name of kohl Ingredients Medical use
With Ithmid-e-
Isfahani
Kohlo-l-dameȇ Ithmid-e-Isfahani (6 dram*), Helix pomatia 
(2 dram), Sea Foam (1 dram), Tutiya (10 dram) that 
processed with fennel extract, Myrobalan bark 
(2 dram)
Eyes with permanent 
moisture and sometimes 
lachrymation (Dameè)
Kohlo-l-basalighoon Burned zinc (6 dram), Burned gold and Ithmid-e-Is-
fahani (of each 1 dram )
Lachrymation and blurred 
vision
Kohlo-l-ramādi Ithmid-e-Isfahani, Tutiya, Helix pomatia (of each 
10 dram ), Greater celandine, pearl (of each 2 dram)
Trachoma (Sabal), im-
provement of vision, 
strengthening of eyes
Kohlo-l-jawaher Ithmid-e-Isfahani (7 dram), Sulfur (0/5 dram), Silver 
oxide, Gold oxide (of each 12 dram), pearl (3 dram), 
Saff ron (0/5 dram), Indian cassia (2 dram)
Improvement of vision, 
strengthening of eyes 
Kohl-e-tarsa Ithmid-e-Isfahani (6 dram), Black pepper (1 dram), 
Sulfur (5 dram), Emblic myrobalan, Tutiya (of each 
1 dram), Burned seashell (3 dram)
Eye lachrymation 




Kohl-e- za’ faran Saff ron, Valerian (of each 2 dram), Long pepper (0/5 
dram), Black pepper (1 dang**), Ammonium chloride 
(2 dang), Camphor (0/5 dang)
Itchy eyes (Hekkeh), 
blurred vision
Kohl-e-anzaroot Yellow Brickleaf (3 dram), Starch, White candy(of 
each 1/5 dram ) 
Treatment of eye injuries 
Kohlo-l-bayaz Sea Foam, Burned silver, Burned copper (of each 4 
dram), Valerian, pearl (of each 2 dram), Gum Arabic, 
Gum tragacanth, Sarcocolla, Starch (of each 1 dram)
whitening eyes pupil or 
leukocoria (Bayaz), eye 
injuries and scar treatment
Kohl-e-mazoo Tutiya, Iron oxide (of each 2 dram), Long pepper, 
Dragon’s blood tree (of each 0/5 dram), Burned zinc, 
Oak gall (of each 1 dram), Cardamom, Musk, 
Camphor (of each 1 dang)
Strengthening of eyes, eye-
lid pruritus
Kohl-e-roshanaei Black pepper, Long pepper, Saff ron, Indian cassia, 
Valerian, Opium poppy (of each 1 mesghal***)
Blurred vision, eye lachry-
mation
Weights used in Persian medicine: * One dram = 3.2 gram, ** One dang = 250 milligram, *** One mesghal = 
4.6 gram
Table 1. Some examples of medicinal kohl in Qarābādins
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sumption should be limited.48 Table 2 summarizes the 
information about plants, minerals and animals men-
tioned in this paper.
Conclusion
Attempts to protect the eye against disorders and to 
treat its diseases have been documented since antiquity. 
Th is article has illustrated the diff erent kohl formula-
tions prescribed by Persian physicians, and also their 
application in the protection and treatment of eye dis-
eases in other ancient civilizations such as those of 
Egypt, Rome and Greece. Th ese applications help clar-
ify the importance of this category of formulations. 
Th ey were eff ective; the presence of lead as the main 
component in kohl formulations, along with materials 
such as zinc oxide, provided an eff ective sun blocking 
activity based on natural products.
Th e eff ectiveness of kohl largely justifi es its use as a 
cosmetic product from ancient times to the very recent 
era. Because many kohl dosage forms were repeated in 
several Qarābādins, across several centuries, their side 
eff ects and toxicity were probably gradually diminished 
and limited by the removal of the most toxic ingredi-
ents and reduction in the quantities of others. Th ese 
observations have been supported by recent studies.49 
Consequently, the historical importance of the use of 
kohl as one of the most common ophthalmic products 
in Persian medicine should be considered.
Persian name English name Scientifi c name Family
Badiyan (Razianeh) Fennel Foeniculum vulgare Mill. Apiaceae
Ahlilaj (Halileh) Myrobalan Terminalia chebula Retz. Combretaceae
Mamiran Greater celandine Chelidonium majus L. Papaveraceae
Za’ faran Saff ron Crocus sativus L. Iridaceae
Sonbol-o-l-tib Spikenard Nardostachys jatamansi (D.Don) DC. Caprifoliaceae
Dārfelfel Long pepper Piper longum L. Piperaceae
Felfel Black pepper Piper nigrum L. Piperaceae
Kafoor Camphor Cinnamomum camphora (L.) J.Presl Lauraceae
Anzaroot Yellow brickleaf Penaea mucronata L. Penaeaceae
Sazaj-e-Hindi Indian cassia Cinnamomum tamala (Buch. -Ham.) T.
Nees & Eberm.
Lauraceae
Samgh-e-Arabi Gum Arabic Acacia senegal (L.) Willd. Leguminosae
Katira Gum tragacanth Astragalus tragacantha L. Leguminosae
Dam-o-l-akhavein (Khoon Sia-
vashan)
Dragon’s blood tree Dracaena cinnabari Balf.f. Asparagaceae
Afes (Mazoo) Oak gall Quercus infectoria G.Olivier Fagaceae
Ghagholeh (Hel) Cardamom Elettaria cardamomum (L.) Maton Zingiberaceae
Amlaj (Ameleh) Emblic myrobalan Phyllanthus emblica L. Phyllanthaceae
Afi yun Opium poppy Papaver somniferum L. Papaveraceae
Ithmid-e-Isfahani Lead sulphide - -
Marghashitha (Hajaro-l-noor) Iron sulfur - -
Shenj (Halazoon) Helix pomatia - -
Zabad-o-l-bahr (Kafe darya) Sea Foam - -
Tutiya Zinc oxide - -
Shadanaj Iron oxide - -
Nooshador Ammonium chloride - -
Mordarsang Plumbum oxidum - -
Marjan Coral - -
Morvarid (Lo’ lo) Pearl - -
Yaghoot Ruby - -
La’ l Garnet - -
Zomorrod Emerald - -
Firoozeh Turquoise - -
Aghigh Opal - -
Sadaf Seashell - -
Table 2. Names of plants, minerals and animals mentioned in this paper
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Th e emergence of chemists’ shops in 
Wimbledon, South London, 1837-1901: 
using trade directories and registers to 
track local pharmacies 
Norma Cox and Stuart Anderson
Abstract 
Th is contribution describes the development of chem-
ists’ shops in Wimbledon Village in south west London 
during the Victorian era, between 1837 and 1901. Th e 
number of shops doubled after 1860 following a sub-
stantial increase in population. Th e main source of ev-
idence for this study is trade directories, which are a 
valuable source of information about local businesses. 
Th ey enable researchers to track the growth and move-
ment of particular trades and services and those in-
volved in them over extended periods of time. Th e ori-
gins and development of trade directories in the London 
area during this period are also described. 
Introduction
Today, there is only one community pharmacy (or 
chemist’s shop as they were usually known) in Wimble-
don Village, the name given to the area at the top of 
Wimbledon Hill along the High Street, Church Street 
and the immediate streets in the vicinity. It is at the 
heart of the district in south west London that is known 
throughout the world for the Wimbledon Tennis 
Championships, but in the mid-nineteenth century it 
was within the boundaries of the county of Surrey. 
Th e pharmacy is located at 80 High Street, and it 
traded as D. E. Davies until 2016. D.E. Davies was the 
pharmacist-proprietor from 1922 until 1938. Today the 
pharmacy is known simply as Wimbledon Pharmacy. 
But in the 1980s there were two community pharma-
cies in the Village – that of D.E. Davies (then at 76 
High Street), and the Watson Pharmacy at 23 High 
Street. Th e fi rst author worked in both pharmacies as a 
locum pharmacist during the 1980s, and she has writ-
ten previously elsewhere about these shops.1 Following 
that study she began to investigate the emergence of 
community pharmacies in Wimbledon Village (then 
simply known as Wimbledon) as the village expanded 
rapidly during the Victorian era. 
Th e Victorian Age is defi ned as the period spanning 
the reign of Queen Victoria, from her accession to the 
throne in 1837 until her death in 1901.2 It was a time 
of great industrial change and prosperity, and was also 
largely a time of peace. Textile and machinery busi-
nesses thrived as people poured into the cities for work. 
Th e population of England and Wales was 16.8 million 
in 1851, and this had doubled to 30.5 million by 1901. 
Wimbledon continued to be administratively located 
in the county of Surrey until 1965, when it became part 
of the London borough of Merton. 
It was a ‘genteel village,’ and was home to the gen-
try.3 Th ese elite citizens lived in large elegant houses 
near to the Common,4 for the area had become very 
prosperous. Th ere were shops in the high street, but 
Wimbledon Village was quiet and undeveloped. Th e 
station at the bottom of the hill had little eff ect on 
Wimbledon, yet as the railways developed their advance 
brought about massive changes in communication and 
society. It was not until the arrival of more railways over 
the 14-year period between 1855 and 1869 that what 
later became the London suburb of Wimbledon devel-
oped.5 Increasing population created a demand for ser-
vices and facilities, including chemists’ shops.
Th e Registers of Chemists and Druggists in the Vic-
torian Era 
Th e fi rst chemist shop in London had been opened 
nearly 500 years earlier, in 1345. Th e name ‘apothecary’ 
was used to describe the pharmacists of the day, but by 
the seventeenth century London apothecaries were able 
to examine patients and administer prepared medi-
cines. Th e Apothecaries could not charge for the exam-
inations, only for the medicines.6 By the end of the sev-
enteenth century the physicians and apothecaries were 
locked in confl ict. Th e Apothecaries consolidated their 
position by becoming ‘general practitioners in physic, 
surgery, pharmacy and midwifery’. Chemists and drug-
gists emerged as the new class of compounders of med-
icine.7 
Th e Victorian Age saw rapid developments in the 
evolution of pharmacy as a profession. Th e Pharmaceu-
tical Society of Great Britain was founded in 1841 by 
a group of prominent chemists and druggists in order 
to protect their trade from unqualifi ed practitioners.8 
In the early nineteenth century anyone could practise 
as a chemist and druggist, and unqualifi ed persons were 
threatening the jobs of the qualifi ed. Th e new Society 
therefore set education standards, with the requirement 
of entry by examination. Th ey published annual lists of 
recognised chemists and druggists (members, associates 
and apprentices) in the Pharmaceutical Journal from 
1841.9 
With passage of the Pharmacy Act in 1852 a Regis-
ter of Pharmaceutical Chemists was kept for the fi rst 
time. Th e Register was kept by the Pharmaceutical So-
ciety, and it included only the names and addresses of 
the proprietors of chemists’ businesses. It was not until 
the later Pharmacy and Poisons Act was passed in 1868 
that examination and registration became mandatory, 
although membership of the Pharmaceutical Society of 
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Great Britain remained voluntary until 1933.10 A sepa-
rate Register of Chemists and Druggists was kept of those 
who had completed the Minor Examination. Separate 
Registers continued until 1954.
Th e Registers of Pharmaceutical Chemists and of 
Chemists and Druggists are valuable sources for phar-
maceutical historians, especially for tracing the move-
ment of individuals over their lifetimes. However, they 
are less helpful in tracking the growth of chemists busi-
nesses in particular communities. A Register of Prem-
ises is available, but this only dates from 1937, having 
been made a requirement by the 1933 Pharmacy and 
Poisons Act. Before then trade directories provided a 
valuable source of information about the shifting pat-
terns of chemists’ businesses.
Th e origin of trade directories 
Collins Dictionary defi nes a directory as ‘a book which 
gives lists of facts, for example people’s names, address-
es, and telephone numbers, or the names and addresses 
of business companies, usually arranged in alphabetical 
order’.11 A trade directory has been defi ned as ‘a book 
containing alphabetical lists and information about 
companies and organizations involved in trade in a par-
ticular area’.12 
Trade directories have a long history, the fi rst rec-
ognized London trade directory having been published 
in 1677.13 Since then many diff erent types of directory 
have been published. Th ey vary greatly in format and 
scope; some are very specialist, such as lists of medical 
practitioners, or householders in Clapham. Others were 
all-embracing general directories, such as Kelly’s Post 
Offi  ce London Directory. Between these extremes were 
a wide variety of directory sub-types.14 
Also classifi ed as directories were a wide range of 
other publications that provided information to local 
residents and businesses. Th ese included almanacs and 
calendars, but not registers, as these were organized on 
a nationwide rather than local basis. 
Directories had two purposes as a reference source: 
to help people fi nd those with trades, and for travelling 
salesmen to identify promising sales leads. Trade Direc-
tories were an important means of advertising in ear-
lier centuries. Many of these old directories have now 
been transcribed or scanned and can be used to track 
ancestors as their businesses moved or developed. 
Th e directories were compiled by surveyors knock-
ing on doors to gather information. In the early direc-
tories, people were eligible to be included if they had a 
trade (for example, dress maker, chimney sweep, butch-
er or shop keeper). Gentry and clergy were also includ-
ed in the early directories. Farmers were not included 
in most of the Pigot’s directories, but were in others. 
Directories were usually a combination of gazet-
teers and trade directory. Th ey contain an immense 
amount of information about towns and villages, their 
facilities in the year of the directory, their history, and 
lists of all the people in each area who have trades. Not 
only businesses and shops were listed; so too were or-
dinary people working as gardeners, blacksmiths, 
seamstresses, dress makers, chimney sweeps and so on. 
It is often possible to reconstruct their lives, with de-
tails of things happening around them in the place 
where they lived.
Later directories were often presented in three sec-
tions. First was a ‘county listing’ of places, with descrip-
tions, facilities and history; second was a ‘court direc-
tory’, which listed private residents, but not all of them; 
third was a ‘classifi ed trade directory’, listing all those 
people with trades in each place. Th e court directory 
section became the place where ordinary private resi-
dents were listed; the section was later renamed ‘private 
residents’.
Kelly’s Post Offi  ce London Directory 
Th e best known of the trade directories were those pub-
lished under the name Kelly. Kelly’s Directory (or more 
correctly, the Kelly’s Post Offi  ce and Harrod & Co. Di-
rectory) listed all businesses and tradespeople in a par-
ticular city or town, as well as a general directory of 
postal addresses of local gentry, landowners, charities, 
and other facilities. It was fi rst published in 1799.15 
Th e Post Offi  ce London Directory was fi rst pub-
lished under the title Th e New Annual Directory for the 
Year 1800. It was renamed the Post Offi  ce Annual Di-
rectory in 1801; the Proprietors – Messrs Ferguson and 
Sparke – were Inspectors of the Inland Letter Carriers, 
the postmen who delivered letters from outside Lon-
don, and they claimed the patronage of the Postmaster 
General, Earl Gower. Th e change of title gave it the aura 
of a semi-offi  cial publication, which the owners capital-
ized at every opportunity. 
It became the Post Offi  ce London Directory from 
1816, and soon saw off  its principal rival, Kent’s Origi-
nal London Directory. Th e principal objective and intent 
of the publication was, they claimed ‘to aff ord accurate 
and useful information to the public with respect to the 
names, occupations and places of residence of the mer-
chants, tradesmen and others carrying on business or 
residing in the metropolis’.16
In 1835 or 1836 Frederic Festus Kelly became chief 
inspector of letter-carriers for the inland or general post 
offi  ce and took over publication of the Post Offi  ce Lon-
don Directory. Its copyright was held in private hands, 
despite its semi-offi  cial association with the post offi  ce. 
Kelly had to purchase it from the widow of his prede-
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cessor, which he did in 1837 (the year of Queen Victo-
ria’s accession to the throne). He introduced a number 
of minor changes, including people’s Christian names 
and titles for the fi rst time. 
From 1840 Kelly’s Post Offi  ce London Directory in-
corporated a classifi ed trade directory. Kelly founded 
Kelly & Co. and he and various family members grad-
ually expanded the company over the next several dec-
ades, producing directories for an increasing number of 
UK counties and buying out or putting out of business 
various competing publishers of directories.17 Th e fi rst 
directories of counties outside London were published 
by Kelly in 1845 and during the next sixteen years the 
series was extended throughout England. 
Other publications followed, including the Hand-
book to the Titled, Landed and Offi  cial Classes (1875) 
and Merchants, Manufacturers and Shippers (1877). In 
1897, Kelly & Co Ltd became Kelly’s Directories Ltd, 
and the full title of the Directory became Th e Post Of-
fi ce London Directory for 1899, comprising, amongst oth-
er information, offi  cial, street, commercial, trades, law, 
court, parliamentary, postal, city and clerical, conveyance 
and banking directories’. 
Th e name Kelly’s Directories Ltd remained for an-
other 106 years before fi nally being renamed Kelly-
search in 2003 to refl ect its focus away from hard copy 
directories and towards an Internet-based product 
search engine. 
Competitors in the trade directory business
Trade Directories were a lucrative business and soon 
others entered the market. A fi rst edition of William 
Robson’s New London Directory appeared in 1819. Th is 
ran to 24 editions, the last produced by Bowtell & Co. 
in 1843. James Pigot published his fi rst directory in 
1811 in his native Manchester. He produced his fi rst 
London Directory in 1822. Robson and Pigot were in 
direct competition throughout the 1820s and 1830s. 
Pigot fi nally withdrew from the London directory mar-
ket in 1841, following change at the Post Offi  ce London 
Directory. 
Later Pigot & Co. published the Royal National and 
Commercial Directory before being acquired by Isaac 
Slater Ltd. In 1892 Kelly’s Directories Ltd acquired the 
majority of shares in Isaac Slater Ltd, and the fi rm of 
William White of Sheffi  eld was absorbed in 1898. 
Kelly’s innovations tempted yet others to enter the 
market, with the directories getting bigger and bigger. 
In 1844 R. Th ompson introduced a comprehensive di-
rectory that included commercial and classifi ed trade 
sections. In 1861 J.S.C. Morris published Th e Business 
Directory of the Manufacturing and Commercial Cities of 
England. Volume 3, published in 1862, covered Lon-
don. At the same time Ashbee & Co. published a Mer-
chants and Manufacturers Pocket Directory. 
Directories for the Wimbledon area
With the rapid growth of London during the Victorian 
period a single trade directory covering London and its 
suburbs was no longer viable. Directories published in 
multiple volumes were the answer. Th e market for local 
suburban directories became highly competitive from 
the mid-1880s. London directories were the fi rst to have 
house by house, street by street listings of householders 
(even those without recognised trades). Th is feature was 
gradually introduced in most other counties, but only 
for the main towns. Some counties, such as Essex, nev-
er had street directories.
In 1881 Edwin Trim & Sons of Wimbledon took 
the initiative and published Trim’s Wimbledon & Mer-
ton Directory and Trade Advertiser for July-December 
1881. Th is was followed in 1885/86 by Kelly’s, who 
published their Post Offi  ce London and Suburban Local 
Directory. Section 10 covered nine suburbs in south 
west London: Wandsworth, Wimbledon, Tooting, 
Roehampton, Putney, Barnes, Mortlake, Kew and 
Richmond. Th eir directory for Wimbledon, Merton, 
Mitcham, Sutton and District was published continu-
ously between 1891 and 1940. 
Wimbledon Chemists and Druggists listed in Trade 
Directories 
Trade directories are a very useful source of informa-
tion on Wimbledon occupations during the Victorian 
Age. In the directories of the early to middle nineteenth 
century there were no chemists and druggists listed for 
Wimbledon in the years 1838,18 183919 and 1840.20 
Th ere were two surgeons listed in the trade directories 
for Wimbledon, so a wider search of Surrey was made 
to clarify if chemists and druggists, surgeons, and 
apothecaries were grouped together. 
Th is was found not to be the case, for in Pigot’s di-
rectory for 1839, Richmond, Surrey had four ‘chymists 
and druggists’ and Wandsworth, Surrey had three.21 
Th e two Wimbledon surgeons were John Sanford and 
Th omas Ellis Tapley. In the 1845 Post Offi  ce Direc-
tory, Mr Th omas Tapley is listed as a chemist and 
druggist.22 He is listed again as a chemist and druggist 
in an 1846 directory,23 in an 1851 directory24 and in 
an 1855 directory, where his name is stated as Th omas 
Ellis Tapley.25 It was not possible to trace Mr Th omas 
Tapley for the years 1856-1859 as the directories for 
Wimbledon were not available. His name was not list-
ed in the trade directory of 1860.26 Th e 1860 directory 
showed that there were two chemists and druggists in 
Wimbledon; one was Mr Charles Bland, High Street, 
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and the other was Mr George W. Snowdon, High 
Street. 
Kirkman, High Street Wimbledon appears for the fi rst 
time. Mr George W. Snowdon had disappeared from 
the directory. 
Th ese two chemists – Mellin and Kirkham – are 
listed in subsequent directories for the years 1872-
1887.33, 34, 35, 36, 37, 38, 39, 40, 41 A change is seen in the di-
rectory for 1888.42 Mr Mellin’s name is not in the di-
rectory; it had been replaced by Mr J.D.S. Pooley, and 
the address given was 36 High Street, Wimbledon. T.E. 
Kirkman is still listed as 30 High Street Wimbledon. 
In the directories for the years 1890-189643, 44, 45, 46, 47 
the names of Mr T.E. Kirkman, chemist at 30 High 
Street and Mr J.D.S. Pooley, chemist at 36 High Street 
Wimbledon are listed.
In the 1898 directory Mr T.E. Kirkman is chemist 
at 76 High Street, Wimbledon. Th e shop at 30 High 
Street, Wimbledon was now a drapers. Mr J.D.S. 
Pooley was still at 36 High Street, Wimbledon.48 Th e 
same listings are seen in the 1899 directory49 and in the 
annual registers up to 1901.50 Table 1 shows a summa-
ry of these Chemists and Druggists details.
Although Mr Th omas Ellis Tapley was the fi rst per-
son listed as a chemist and druggist in Wimbledon in 
1845, it  is interesting that he had practised as a surgeon 
in Wimbledon for at least nineteen years,51 before be-
coming a Chemist and Druggist. Although some job 
descriptions in the early nineteenth century were am-
biguous, for John Sanford of Wimbledon was an apoth-
ecary in 1817, a surgeon in 1841 and a retired medical 
practitioner in 1851.52 
Th is examination of the directories indicate that, 
once established in a particular pharmacy, individuals 
tended to remain there for some years, although this 
may have involved a relocation of the premises. Th e pe-
riods of service of the named pharmacists are summa-
rised in Table 1. 
Wimbledon Chemists and Druggists listed in Regis-
ters of Pharmaceutical Chemists
Mr Tapley’s name appeared as a chemist and druggist 
in 1845, four years after the foundation of the Pharma-
ceutical Society of Great Britain. His name did not ap-
pear in the published lists of the Pharmaceutical Soci-
ety,53 but this was not unexpected, as the mandatory 
conditions of the Pharmacy Act did not come into force 
Figure 1. Pooley & Co. 36 High Street, Wimbledon 
(Source: Kelly’s Directory of Wimbledon 1940)
Table 1. Summary of chemists and druggists in business in Wimbledon 1845-1901
Years in business First pharmacist Years in business Second Pharmacist 
1845 - 1855 Th omas Ellis Tapley - -
1860 - 1862 Charles Bland 1860 - 1870 George Snowdon
1862 - 1888 Joseph Mellin - -
1888 - 1901 J.D.S. Pooley 1870 - 1901 T.E. Kirkman
Wimbledon Chemists and Druggists listed in Tele-
phone Directories 
In the 1862 Post Offi  ce directory of Surrey Mr Bland 
had gone. Listed were George W. Snowdon, chemist, 
High Street Wimbledon and Joseph Phillips Mellin, 
chemist, High Street Wimbledon.27 Th ese two chemists 
were listed in the directories for 186328 and 1865.29 In 
the 1866 directory30 only the name of George W. Snow-
don is listed. In the directory of 186831 only the name 
of Joseph P. Mellin is listed. In the directory for 187032 
Joseph Phillips Mellin, chemist High Street, Wimble-
don is listed, and a new chemist, Mr Th omas Elton 
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until 1868.54 Mr Tapley has also been called Mr Top-
ley,55 and his address in the 1841 census was 31 High 
Street North, Wimbledon.56 His surname was in fact 
Tapley; he was born in Exeter, Devon in 1798, as shown 
in the 1851 census.57 
Mr George Wrangham Snowdon was the fi rst 
Wimbledon pharmacist whose name was published in 
the lists of the Pharmaceutical Society.58 He registered 
in 1863. Mr Joseph P. Mellin is listed in the 1869 reg-
ister of Chemists and Druggists and Pharmaceutical 
Chemists.59 He registered on 31 December 1868 and 
was in business before August 1868. Both of these High 
Street businesses were listed in the directories for 1860, 
but it was not possible to determine which was the old-
er, as the trade directories for 1856-1859 were missing.
Mr J.D.S. Pooley took over Mr Mellin’s pharmacy 
at 36 High Street in 1888. Locals remembered Mr 
Pooley’s shop, for it had two large glass carboys in the 
shop windows, one red the other blue, which were still 
there in the 1920’s.60 Number 36 High Street is in a 
parade of shops where many of the buildings were 
Georgian.61 Figure 2 shows the building today. 
Victorian era has shown that the number doubled after 
1860, following a substantial increase in population. 
Th is rise in population was due to the development of 
Wimbledon Village. Foundation of the Pharmaceutical 
Society of Great Britain in 1841 and the subsequent 
professionalization of pharmacy63 led to increased job 
security and professional status for chemists and drug-
gists, and this is refl ected in the long service given by 
the Wimbledon Village chemists and druggists. Th e 
Pharmacy Act of 1868 set the standards for commu-
nity pharmacy we still see today. Numbers 36 and 76 
High Street Wimbledon still remain, but not as com-
munity pharmacies. Th eir architecture is a reminder of 
the history of Wimbledon Village. 
Trade Directories constitute an important source 
for tracking the rise and fall of pharmacy businesses in 
local communities in Great Britain, for identifying the 
names and addresses of their owners as well as the 
length of time they were in business. Th ey are of par-
ticular value during the nineteenth century when other 
sources of this information are much more limited. 
Registers of Pharmaceutical Chemists and Chemist and 
Druggists can supplement but not replace them, and 
the Register of Premises is only of help after its fi rst 
publication in 1937.
Figure 2. 36 High Street, Wimbledon today (Source: 
Photograph by Norma Cox 2017)
Figure 3. 74-76 High Street, Wimbledon today (Source: 
Photograph by Norma Cox 2017) 
Mr Kirkman registered with the Pharmaceutical Soci-
ety of Great Britain on 31 December 1868, having been 
in business before August 1868.62 Mr Kirkman took 
over Mr Snowdon’s shop in 1870. Mr Kirkman’s busi-
ness moved premises in 1899 to 76 High Street, which 
was part of a new building, comprising a court dresser 
at 74, a bank at 75 and a nurseryman also at number 
76. Figure 3 shows the building today, with number 76 
on the right. 
Conclusion
Th is small investigation into the number of chemists 
and druggists in Wimbledon High Street during the 
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D O C U M E N T S  A N D 
S O U R C E S
Major accessions to repositories in 2016 
relating to Pharmacy and Chemistry
Th e National Archives, Kew, London
Th e National Archives (TNA) in London publishes 
an annual list of Accessions to Repositories which collates 
information provided by over 200 record repositories 
throughout the British Isles. It lists manuscript acces-
sions received during the previous 12 months. Th is in-
formation is then edited and used to produce 38 the-
matic digests, one of which is entitled “Pharmacy and 
Chemistry”. Th e thematic digests are made available in 
full on the TNA website, and are also distributed for 
publication in learned journals and newsletters. See 
http://www.nationalarchives.gov.uk/accessions/ 
2016/16digests/default.htm.
In 2013 Th e National Archives replaced its old cat-
alogue with a new online platform called DISCOVERY, 
which allows users to search for records held on it. Th is 
also incorporates information from other sources de-
scribing records held in archives elsewhere, as part of 
TNA’s Finding Archives project. Th is project oversaw 
the integration of content from the National Register 
of Archives (NRA), the Directory of Archives (AR-
CHON), Access to Archives (A2A) and the Manorial 
Documents Register (MDR) into DISCOVERY.
Th e DISCOVERY platform now provides a single 
point of online access to catalogue and organisational 
data from across the archive sector, including Acces-
sions to Repositories. Th e platform provides descriptive 
and access information about millions of records held 
in over 2,500 archives in the United Kingdom and 
overseas. It has now integrated approximately 10 mil-
lion catalogue descriptions from Access to Archives, 
along with over 250,000 National Register of Archives 
and Manorial Documents Register entries.
In addition to the “Pharmacy and Chemistry” 
theme some records of possible interest to pharmaceu-
tical historians may be listed under other headings, es-
pecially under the “Health and Medicine” theme. Ac-
cessions during 2016 listed under both themes which 
may be of interest to pharmaceutical historians are list-
ed below.
Major accessions to repositories in 2016 relating to 
“Pharmacy and Chemistry” are as follows:
LOCAL:
Archifau Ynys Mon / Anglesey Archives:
William Prytherch Parry, ophthalmic optician and 
pharmacist, Llanfairpwll: papers c1960 (WDAAX).
Coventry Archives & Research Centre:
AL Smith, chemist, Coventry: prescription ledgers 
c1900-1950 (PA3095).
Wyley’s Ltd, pharmacists and chemists, Coventry: for-
mula book, receipts c1757-1950 (PA3108).
Hull History Centre (Hull City Archives):
Pharmaceutical Society of Great Britain, Hull: photo-
graph album, visitor’s book, printed material, list of of-
fi cers, records rel to early warning system c1869-1998 
(C DSCA).
Oxfordshire History Centre:
Pharmaceutical Society of Great Britain, Oxford and 




Sir John Warcup Cornforth (1917-2013), chemist: per-
sonal papers incl photographs c1950-2000
(COR/3).
UNIVERSITY: 
London University: King’s College Archives:
John Louis William Th udichum (1829-1901), physician 
and chemist: papers incl research notes, letters and 
spectrographic images 1867-1886 (Acc 3381).
_______________________________________________
Major accessions to repositories in 2016 relating to 
“Health and Medicine” which may be of interest to 
pharmaceutical historians include the following:
LOCAL:
Warwickshire County Record Offi  ce
Samuel Hollingsworth Agar (1857-1941), physician: 
prescription book 1911-1942 (CR4825).
SPECIAL:
Wellcome Library
DrugScope, charity: records rel to drugs and drug pol-
icy c1930-2000 (SA/DRS).
Recipe and prescription book, mostly in Latin c1740-
1760 (MS.9215).
Manuscript collection of medical recipes in several 
hands, with printed recipes pasted on the inside covers 
c1800 (MS.9221).
UNIVERSITY:
Warwick University: Modern Records Centre
Release, charity for drug users: papers and publications 
1969-1979 (1132).
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B O O K  R E V I E W
A Brief History of Pharmacy: Humanity’s 
Search for Wellness
By Bob Zebroski
New York: Routledge, 2016. Pp. 250. Hardback, price 
£110.00. ISBN 978-0-415-53783-4. Softback, price 
£30.99. ISBN 978-0-415-53784-1. Ebook, price 
£26.39. ISBN 978-0-315-68583-0.
if any, by the reader can be assumed. Th e appearance 
of this latest book – a single author volume by Bob Ze-
broski – is therefore to be warmly welcomed.
Zebroski, who is professor of history and chairper-
son of the Liberal Arts Department at the St. Louis 
College of Pharmacy, is very clear about his target au-
dience; as the cover states ‘this accessible survey of phar-
maceutical history is essential reading for all students 
of pharmacy.’ With this in mind the layout of the book 
is designed to grab and maintain the reader’s attention. 
Each chapter starts with an overview question which 
the chapter then proceeds to answer. Th e main text is 
interspersed with boxes and pop-up items to retain the 
reader’s interest, and each chapter is supported with il-
lustrations, charts and diagrams. A summary, key 
words and a list of learning outcomes indicating what 
the reader should be able to do having read the chapter 
are provided at the end of each chapter. All this bodes 
well for an absorbing and informative, if brief, account 
of the history of pharmacy.
Th e book itself has a brief introduction to ‘the es-
sentials of pharmacy’ which is followed by 16 chapters 
of varying lengths but usually of between 10 and 20 
pages. Th e fi rst eight cover the history of pharmacy up 
to the early nineteenth century. Starting with pre-his-
toric pharmacy in chapter 1 they progress through 
pharmacy in the river civilisations of Mesopotamia, 
Egypt, ancient India and China. Chapter 4 deals with 
pharmacy in ancient Greece and Rome, before succes-
sive chapters deal with medieval pharmacy in the west 
and then the Arab and Islamic worlds. Chapter 7 tells 
the story of pharmacy during the European Renais-
sance and the early Modern era, with chapter 8 moving 
on to eighteenth and early nineteenth century pharma-
cy, tracing the evolution of the apothecary to the chem-
ist and then the pharmacist.
Th e second half of the book is concerned almost ex-
clusively with the history of pharmacy in the United 
States, which is then explored in rather greater detail. 
Chapter 9 covers colonial and early American pharma-
cy, while chapter 10 focuses on the era of alternative 
and patent medicine. Successive chapters deal with the 
development of pharmacy practice, the history of phar-
macy education, and the origin and growth of the phar-
maceutical industry. Th e fi nal three chapters deal re-
spectively with the emergence of the chain drugstore, 
the impact of federal legislation and the history of hos-
pital pharmacy and the rise of clinical pharmacy. Dis-
appointingly there is then no attempt at drawing to-
gether key themes across time and place in a concluding 
chapter.
Each chapter is extensively referenced, with typi-
cally around 40 references, although individual chap-
Reviewed by Stuart Anderson
Capturing the entire history of pharmacy in a single 
volume is a momentous challenge, and not surprisingly 
it is not undertaken very often. In the English language, 
the last revision of the defi nitive American account, 
Kremers and Urdang’s History of Pharmacy (fi rst pub-
lished in 1940) appeared over 40 years ago, in 1976. 
Such projects require many diffi  cult choices; about the 
relative attention to be focussed on the history of phar-
macy in a particular country versus developments 
around the world; about the division of available space 
between diff erent time periods – from antiquity to the 
present day; and about what level of prior knowledge, 
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ters list between 13 and 52 references. However, overall 
the source material is extremely limited; a very high 
proportion of the references come from a very small 
number of very old secondary sources. Charles Lawall’s 
1927 book, Four Th ousand Years of Pharmacy, is exten-
sively referenced throughout the book, as are some of 
the early British histories of pharmacy including Woot-
ton’s 1910 two volume Chronicles of Pharmacy, Th omp-
son’s 1929 Th e Mystery and Art of the Apothecary and 
Grier’s 1937 History of Pharmacy.
Th is reliance on early British contributions to the 
history of pharmacy is a little surprising. In Britain 
three important books appeared during the 1960s, 
starting with Matthew’s scholarly History of Pharmacy 
in Britain in 1962. It was followed by George Trease’s 
chronological account of Pharmacy in History in 1964, 
and Poynter’s edited volume on Th e Evolution of Phar-
macy in Britain followed in 1965. Whilst a number of 
important histories have appeared since, they have usu-
ally been concerned with specifi c aspects of the history 
of pharmacy such as its institutions, education or arte-
facts. Th e most recent attempt in Britain to provide an 
overview of pharmacy history has been Making Medi-
cines: A Brief History of Pharmacy and Pharmaceuticals, 
published in 2005 by Th e Pharmaceutical Press. 
Perhaps rather less surprising is the selective use of 
Sonnedecker’s 1979 revision of Kremers and Urdang’s 
History of Pharmacy. Extensive use is also made of 
George Bender’s 1966 Great Moments in Pharmacy, and 
of Cowen and Helfand’s 1990 Pharmacy: An Illustrated 
History. Other extensively used but rather more recent 
secondary sources include Roy Porter’s 1997 Th e Great-
est Benefi t to Mankind: A Medical History of Humanity 
and Barbara Griggs’ 1997 Green Pharmacy: Th e History 
and Evolution of Western Herbal Medicine. 
All of these might more appropriately and helpfully 
have been provided as a suggested reading list. How-
ever, once removed from the reference lists some of the 
latter would be very thin indeed. Even many of those 
remaining were published some time ago, such as Rid-
dle’s 1985 book Diascorides on Pharmacy and Medicine 
and some of the early works of Scarborough and 
Griff enhagen. Only in the later chapters on the recent 
history of American pharmacy do any references dated 
after 2000 make an appearance.
Th ere are diffi  culties with placing too great a reli-
ance on old secondary sources. Firstly, there are some-
times substantial diff erences in the diff erent accounts 
given of the early history of pharmacy. Some of them 
are themselves inadequately referenced, or depend for 
their source material on diff erent earlier texts. Unfor-
tunately quite a number of errors have crept into this 
book. British readers will be surprised to learn that the 
compressed pill or ‘tablet’ was discovered in the 1860s 
by a Philadelphia wholesale druggist called John Dun-
ton (a patent for a die and punch had been taken out 
by Brockeden in 1843); and that the Society of Apoth-
ecaries of London was founded in 1606 (it was 1617).
Inevitably in an intentionally brief history of phar-
macy some important information has to be omitted. 
But a book aimed at a new generation of pharmacy stu-
dents needs to cover a few essentials. Not all pharmacy 
students can be assumed to have a sound understand-
ing of historical methods and their relevance to phar-
macy. With pharmacy history – as in history more gen-
erally – students need to be constantly asking whose 
history is being presented, to know how to deal with 
incomplete evidence, and to place historical accounts 
in their social, cultural, economic and political con-
texts. Th ey need a good understanding of historical 
sources, both primary and secondary, from the written 
word to oral history and artefacts; and they also need 
to be able to critically interpret historical information 
readily available on the internet.
A fi nal observation relates to the title of the book. 
Although the title makes no mention of pharmacy in 
the United States Zebroski does include a sub-title, ‘hu-
manity’s search for wellness’. But those searching for 
wellness as a theme linking the chapters will look in 
vain. Rather than wellness the book records mankind’s 
constant battle with sickness. It provides a brief account 
of mankind’s search for relief from their ailments, for 
ways of preventing sudden death, and for delaying its 
premature arrival; and it gives a brief account of how 
some individuals came to occupy the occupational 
space of those off ering remedies for such concerns.
But a more important objective for pharmaceutical 
historians in teaching pharmacy students today is sure-
ly to demonstrate that the history of pharmacy is a sub-
stantial, dynamic and important fi eld of study in its 
own right, a fi eld that continues to generate a stream of 
high quality original research, and which requires us to 
constantly question, revise and correct our understand-
ing of pharmacy’s history. Th is book feels like a missed 
opportunity to provide the sort of resource needed by 
the pharmacy students of both today and tomorrow.
Reviewer’s address: Stuart Anderson, Centre for His-
tory in Public Health, London School of Hygiene & 
Tropical Medicine, London WC1E 7HT, UK.
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